The global oncology injection drug market is expected to grow at a CAGR of 5.5% during the forecast period, from 2021 to 2030. The growth of this market is attributed to the increasing number of cancer cases and rising awareness about cancer treatment. The global oncology injection drug market is segmented by type, application, and region. On the basis of type, it is classified into organs, central nervous system (CNS), circulatory/musculoskeletal system (CMS). On the basis of application, it includes lymphoma, myeloma and prostate cancer. Geographically it covers North America (NA), Latin America (LA), Europe (EU), Asia Pacific & Middle East & Africa (APMEA) regions.
North America dominates in terms of revenue share in this market due to high prevalence rates for cancers such as breast cancer and prostate cancer in this region which are treated with injectable drugs such as Herceptin® and Zytiga®, respectively. In addition to that there are many pharmaceutical companies operating in North America which manufacture these drugs for sale globally thereby contributing towards its dominance over other regions such as APMEA where there are less number of manufacturers operating within the region.
-The global Oncology Injection Drug market is expected to grow at a CAGR of 5.5% during the forecast period, 2018-2025.
-The global Oncology Injection Drug market is expected to reach USD 3,814.2 million by 2025 from USD 2,906.6 million in 2018, growing at a CAGR of 5.5% during the forecast period 2018-2025.
-Increasing prevalence of cancer and rising awareness about cancer treatment are some factors driving the growth of this market.
Industry Growth Insights published a new data on “Oncology Injection Drug Market”. The research report is titled “Oncology Injection Drug Market research by Types (Organs, Central Nervous System, Circulatory/Musculoskeletal System), By Applications (Lymphoma, Myeloma, Prostate Cancer), By Players/Companies Taj Oncology, S.G. Biopharm, AdvaCare, Merrimack, Celgene, Allos Therapeutics, Ferring Pharmaceuticals, Genzyme, Eli Lilly, Praecis Pharmaceuticals, Millennium Pharmaceuticals, Debiopharm, Alza, CordenPharma, Pharmascience”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Oncology Injection Drug Market Research Report
By Type
Organs, Central Nervous System, Circulatory/Musculoskeletal System
By Application
Lymphoma, Myeloma, Prostate Cancer
By Companies
Taj Oncology, S.G. Biopharm, AdvaCare, Merrimack, Celgene, Allos Therapeutics, Ferring Pharmaceuticals, Genzyme, Eli Lilly, Praecis Pharmaceuticals, Millennium Pharmaceuticals, Debiopharm, Alza, CordenPharma, Pharmascience
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
236
Number of Tables & Figures
166
Customization Available
Yes, the report can be customized as per your need.
Global Oncology Injection Drug Market Report Segments:
The global Oncology Injection Drug market is segmented on the basis of:
Types
Organs, Central Nervous System, Circulatory/Musculoskeletal System
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Lymphoma, Myeloma, Prostate Cancer
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Taj Oncology
- S.G. Biopharm
- AdvaCare
- Merrimack
- Celgene
- Allos Therapeutics
- Ferring Pharmaceuticals
- Genzyme
- Eli Lilly
- Praecis Pharmaceuticals
- Millennium Pharmaceuticals
- Debiopharm
- Alza
- CordenPharma
- Pharmascience
Highlights of The Oncology Injection Drug Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Organs
- Central Nervous System
- Circulatory/Musculoskeletal System
- By Application:
- Lymphoma
- Myeloma
- Prostate Cancer
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Oncology Injection Drug Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Oncology injection drug is a medication used to treat cancer. It is a type of chemotherapy.
Some of the major companies in the oncology injection drug market are Taj Oncology, S.G. Biopharm, AdvaCare, Merrimack, Celgene, Allos Therapeutics, Ferring Pharmaceuticals, Genzyme, Eli Lilly, Praecis Pharmaceuticals, Millennium Pharmaceuticals, Debiopharm, Alza, CordenPharma, Pharmascience.
The oncology injection drug market is expected to register a CAGR of 5.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Oncology Injection Drug Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Oncology Injection Drug Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Oncology Injection Drug Market - Supply Chain
4.5. Global Oncology Injection Drug Market Forecast
4.5.1. Oncology Injection Drug Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Oncology Injection Drug Market Size (000 Units) and Y-o-Y Growth
4.5.3. Oncology Injection Drug Market Absolute $ Opportunity
5. Global Oncology Injection Drug Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Oncology Injection Drug Market Size and Volume Forecast by Type
5.3.1. Organs
5.3.2. Central Nervous System
5.3.3. Circulatory/Musculoskeletal System
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Oncology Injection Drug Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Oncology Injection Drug Market Size and Volume Forecast by Application
6.3.1. Lymphoma
6.3.2. Myeloma
6.3.3. Prostate Cancer
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Oncology Injection Drug Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Oncology Injection Drug Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Oncology Injection Drug Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Oncology Injection Drug Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Oncology Injection Drug Demand Share Forecast, 2019-2026
9. North America Oncology Injection Drug Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Oncology Injection Drug Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Oncology Injection Drug Market Size and Volume Forecast by Application
9.4.1. Lymphoma
9.4.2. Myeloma
9.4.3. Prostate Cancer
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Oncology Injection Drug Market Size and Volume Forecast by Type
9.7.1. Organs
9.7.2. Central Nervous System
9.7.3. Circulatory/Musculoskeletal System
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Oncology Injection Drug Demand Share Forecast, 2019-2026
10. Latin America Oncology Injection Drug Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Oncology Injection Drug Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Oncology Injection Drug Market Size and Volume Forecast by Application
10.4.1. Lymphoma
10.4.2. Myeloma
10.4.3. Prostate Cancer
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Oncology Injection Drug Market Size and Volume Forecast by Type
10.7.1. Organs
10.7.2. Central Nervous System
10.7.3. Circulatory/Musculoskeletal System
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Oncology Injection Drug Demand Share Forecast, 2019-2026
11. Europe Oncology Injection Drug Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Oncology Injection Drug Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Oncology Injection Drug Market Size and Volume Forecast by Application
11.4.1. Lymphoma
11.4.2. Myeloma
11.4.3. Prostate Cancer
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Oncology Injection Drug Market Size and Volume Forecast by Type
11.7.1. Organs
11.7.2. Central Nervous System
11.7.3. Circulatory/Musculoskeletal System
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Oncology Injection Drug Demand Share, 2019-2026
12. Asia Pacific Oncology Injection Drug Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Oncology Injection Drug Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Oncology Injection Drug Market Size and Volume Forecast by Application
12.4.1. Lymphoma
12.4.2. Myeloma
12.4.3. Prostate Cancer
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Oncology Injection Drug Market Size and Volume Forecast by Type
12.7.1. Organs
12.7.2. Central Nervous System
12.7.3. Circulatory/Musculoskeletal System
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Oncology Injection Drug Demand Share, 2019-2026
13. Middle East & Africa Oncology Injection Drug Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Oncology Injection Drug Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Oncology Injection Drug Market Size and Volume Forecast by Application
13.4.1. Lymphoma
13.4.2. Myeloma
13.4.3. Prostate Cancer
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Oncology Injection Drug Market Size and Volume Forecast by Type
13.7.1. Organs
13.7.2. Central Nervous System
13.7.3. Circulatory/Musculoskeletal System
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Oncology Injection Drug Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Oncology Injection Drug Market: Market Share Analysis
14.2. Oncology Injection Drug Distributors and Customers
14.3. Oncology Injection Drug Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Taj Oncology
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. S.G. Biopharm
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. AdvaCare
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Merrimack
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Celgene
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Allos Therapeutics
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Ferring Pharmaceuticals
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Genzyme
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Eli Lilly
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Praecis Pharmaceuticals
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. Millennium Pharmaceuticals
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. Debiopharm
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. Alza
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. CordenPharma
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. Pharmascience
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
